DVY vs IBB
iShares Select Dividend ETF vs iShares Biotechnology ETF
- • DVY has the lower expense ratio at 0.38% vs 0.44% for IBB.
- • DVY pays a higher dividend yield (3.29%).
Side-by-side metrics
| Metric | DVY | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.38% | 0.44% |
Dividend yield Trailing 12-month yield. | 3.29% | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $23.69B | $11.50B |
YTD return | 17.74% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.51 | 0.60 |
P/E ratio | 14.69 | 25.48 |
Last price | $162.67 | $217.75 |
Inception | — | — |
Issuer | iShares | iShares |
DVY top holdings
| PFE | Pfizer Inc | 2.46% |
| MO | Altria Group Inc | 2.38% |
| HPQ | HP Inc | 2.16% |
| PRU | Prudential Financial Inc | 2.12% |
| TROW | T. Rowe Price Group Inc | 1.99% |
| OKE | ONEOK Inc | 1.84% |
| TGT | Target Corp | 1.68% |
| VZ | Verizon Communications Inc | 1.66% |
| CVX | Chevron Corp | 1.62% |
| KMB | Kimberly-Clark Corp | 1.61% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About DVY
DVY (iShares Select Dividend ETF) is 100 high-dividend-yielding US stocks. Managed by iShares, the fund carries $23.7B in assets under management, an expense ratio of 0.38%, a dividend yield of 3.29%. Its largest holding is Pfizer Inc (PFE), which represents 2.5% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 9.8%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.